Clinical Trial Update: Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

View source ↗

Summary

Trial evaluated Vimpat (lacosamide) as adjunctive therapy to one baseline antiepileptic drug in partial epilepsy; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• Vimpat (lacosamide)

Snippet

Sponsor: UCB Pharma GmbH | Conditions: Epilepsies, Partial | Status: COMPLETED | Results posted: 2014-07-22